Celyad Oncology SA (EBR: CYAD)
Belgium
· Delayed Price · Currency is EUR 0.692
-0.024 (-3.35%)
Dec 20, 2024, 4:30 PM CET
Celyad Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.07 | 0.1 | - | - | 0.01 | 0.01 | Upgrade
|
| Revenue Growth (YoY) | 63.64% | - | - | - | -16.67% | -99.81% | Upgrade
|
| Cost of Revenue | 0.03 | 0.07 | - | - | - | - | Upgrade
|
| Gross Profit | 0.04 | 0.03 | - | - | 0.01 | 0.01 | Upgrade
|
| Selling, General & Admin | 4.32 | 6.25 | 10.56 | 10 | 9.39 | 9.19 | Upgrade
|
| Research & Development | 3.78 | 4.38 | 18.91 | 20.69 | 21.44 | 25.08 | Upgrade
|
| Other Operating Expenses | -0.28 | -1.09 | -4.03 | -3.44 | -4.59 | -4.77 | Upgrade
|
| Operating Expenses | 7.82 | 9.55 | 25.45 | 27.24 | 26.25 | 29.5 | Upgrade
|
| Operating Income | -7.78 | -9.51 | -25.45 | -27.24 | -26.24 | -29.49 | Upgrade
|
| Interest Expense | -0.12 | -0.08 | -0.2 | -0.26 | -0.3 | -0.34 | Upgrade
|
| Interest & Investment Income | 0.1 | 0.03 | 0.01 | 0.03 | 0.05 | 0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | 0.17 | 0.01 | -0.14 | 0.33 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | -0 | 0.11 | 0.17 | 0.16 | Upgrade
|
| EBT Excluding Unusual Items | -7.8 | -9.57 | -25.46 | -27.35 | -26.46 | -29.26 | Upgrade
|
| Impairment of Goodwill | - | - | -0.64 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.18 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.02 | 1.06 | 5 | -0 | 0.03 | - | Upgrade
|
| Asset Writedown | - | - | -34.44 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 14.68 | 0.85 | 9.23 | 0.43 | Upgrade
|
| Pretax Income | -7.82 | -8.51 | -40.87 | -26.5 | -17.2 | -28.64 | Upgrade
|
| Income Tax Expense | -0.06 | -0.06 | 0.07 | 0.01 | - | -0.01 | Upgrade
|
| Net Income | -7.75 | -8.45 | -40.94 | -26.51 | -17.2 | -28.63 | Upgrade
|
| Net Income to Common | -7.75 | -8.45 | -40.94 | -26.51 | -17.2 | -28.63 | Upgrade
|
| Shares Outstanding (Basic) | 35 | 26 | 23 | 16 | 14 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 35 | 26 | 23 | 16 | 14 | 13 | Upgrade
|
| Shares Change (YoY) | 55.53% | 13.84% | 44.80% | 11.92% | 11.33% | 12.39% | Upgrade
|
| EPS (Basic) | -0.22 | -0.33 | -1.81 | -1.70 | -1.23 | -2.29 | Upgrade
|
| EPS (Diluted) | -0.22 | -0.33 | -1.81 | -1.70 | -1.23 | -2.29 | Upgrade
|
| Free Cash Flow | -10.29 | -16.1 | -28.13 | -26.97 | -27.82 | -28.62 | Upgrade
|
| Free Cash Flow Per Share | -0.29 | -0.63 | -1.25 | -1.73 | -2.00 | -2.29 | Upgrade
|
| Gross Margin | 52.78% | 32.35% | - | - | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -10806.94% | -9325.49% | - | - | -524800.00% | -491566.67% | Upgrade
|
| Profit Margin | -10766.67% | -8282.35% | - | - | -344080.00% | -477200.00% | Upgrade
|
| Free Cash Flow Margin | -14284.72% | -15785.29% | - | - | -556300.00% | -476983.33% | Upgrade
|
| EBITDA | -7.44 | -9 | -24.74 | -26.68 | -24.41 | -27.71 | Upgrade
|
| D&A For EBITDA | 0.34 | 0.51 | 0.71 | 0.56 | 1.83 | 1.79 | Upgrade
|
| EBIT | -7.78 | -9.51 | -25.45 | -27.24 | -26.24 | -29.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.